文献速递淋巴瘤

组织细胞肿瘤患者中断靶向治疗后的结局

Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.
PubMed 文献 · Br J Haematol · 2023-07-03

本研究为经机构审查委员会批准的研究,纳入达到完全或部分代谢缓解后中断BRAF和MEK抑制剂的组织细胞肿瘤成人患者,17/22(77%)在中断后出现疾病复发;中断前达完全缓解、携带非BRAFV600E突变及仅接受MEK抑制剂治疗均与无复发生存改善相关。

要点

  • 中断靶向治疗后17/22(77%)患者出现疾病复发。
  • 中断前达完全缓解与非BRAFV600E突变及仅用MEK抑制剂各与无复发生存改善相关。
  • 复发在中断治疗后常见,但部分患者可能适合有限疗程治疗。

核心结论

  • 中断靶向治疗后复发常见,但部分患者可能适合有限疗程治疗。

研究设计与样本

  • 经机构审查委员会批准的研究,纳入组织细胞肿瘤成人患者,在经18-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)评估达到完全或部分缓解后中断BRAF和MEK抑制剂。

主要发现

  • 17/22(77%)患者在中断治疗后出现疾病复发。
  • 中断前达完全缓解、携带非BRAFV600E突变及仅接受MEK抑制剂治疗各与无复发生存改善呈统计学显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Little is known about outcomes following interruption of targeted therapy in adult patients with histiocytic neoplasms. This is an IRB-approved study of patients with histiocytic neoplasms whose BRAF and MEK inhibitors were interrupted after achieving complete or partial response by 18-fluorodeoxyglucose positron emission tomography (FDG-PET). 17/22 (77%) of patients experienced disease relapse following treatment interruption. Achieving a complete response prior to interruption, having a mutation other than BRAFV600E, and receiving MEK inhibition only were each associated with a statistically significant improvement in relapse-free survival. Relapse is common following treatment interruption however some patients may be suitable for limited-duration treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Reiner AS, Durham BH, Yabe M, et al. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol. 2023. PMID: 37400251. doi:10.1111/bjh.18964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。